Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Prometheus Biosciences Inc (NASDAQ:RXDX)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Jan 19|
|Day's Range||34.01 - 36.43|
|52 Week Range||16.11 - 40.49|
Prometheus Biosciences Inc dividends
Prometheus Biosciences Inc has a market cap or net worth of $1.33 billion. The enterprise value is $0.
Prometheus Biosciences Inc has 38.94 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is -12.4876. Prometheus Biosciences Inc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.1088%. The beta is 0.0000, so Prometheus Biosciences Inc's price volatility has been lower than the market average.
In the last 12 months, Prometheus Biosciences Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.
Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD.
The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA..